EMGRAST-M

Main information

  • Trade name:
  • EMGRAST-M VIAL VIAL
  • Dosage:
  • 300MCG(R-HUGMCSF GRANULOCYTE COLONY SIMULATING FACTOR)
  • Pharmaceutical form:
  • VIAL
  • Composition:
  • VIAL
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • EMGRAST-M VIAL VIAL
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

21-11-2013

Danish Pharmacovigilance Update, 26 September 2013

Danish Pharmacovigilance Update, 26 September 2013

In this issue of Danish Pharmacovigilance Update: Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are associated with risk of capillary leak syndrome.

Danish Medicines Agency

7-8-2018

Accofil (Accord Healthcare Limited)

Accofil (Accord Healthcare Limited)

Accofil (Active substance: Filgrastim) - Centralised - Yearly update - Commission Decision (2018)5428 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

1-8-2018

Grastofil (Apotex Europe B.V.)

Grastofil (Apotex Europe B.V.)

Grastofil (Active substance: filgrastim) - Centralised - Yearly update - Commission Decision (2018)5228 of Wed, 01 Aug 2018

Europe -DG Health and Food Safety